Allied-Bristol Life Sciences is forming a new subsidiary, ABLS IV, to enter into an exclusive licensing agreement with Cornell University in relation to a novel class of inhibitors of immunoproteasomes. 30 October 2017
Japan’s Kyowa Hakko Kirin has announced that its marketing authorization application (MAA) for mogamulizumab, for the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least one prior systemic therapy, has been validated by the European Medicines Agency (EMA) and is now under review. 27 October 2017
The financial results for the first nine months of 2017 emphasize the continued growth of the Italian Recordati group, with revenues and profitability increasing significantly, the company announced today. 26 October 2017
Chi-Med, a Chinese biopharma company that is majority owned by the conglomerate CK Hutchison Holdings, has announced that it intends to offer $262 million of American Depositary Shares, each representing one-half of one ordinary share, par value $1 each, on the Nasdaq market. 25 October 2017
Janssen Pharmaceutica, a unit of US healthcare giant Johnson & Johnson, today announced that the pivotal Phase III AMBER study achieved its primary endpoint. 25 October 2017
UK-based specialty pharma company Clinigen Group has acquired International Medical Management Corporation (IMMC), Japan’s largest supplier of unlicensed medicines, for an undisclosed sum. 23 October 2017
US pharma major Eli Lilly today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. 23 October 2017
major AstraZeneca and Merck & Co have submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Lynparza (olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with a decision expected in the second half of 2018. 23 October 2017
The UK’s AstraZeneca has received US FDA approval for Bydureon BCise, a new once-weekly, single-dose autoinjector-based formulation of Bydureon. 23 October 2017
The Canadian subsidiary of Taiho Pharmaceutical, itself a part of Japan’s Otsuka Holdings, says that Health Canada has accepted for review Taiho's New Drug Submission (NDS) for trifluridine (FTD) and tipiracil (TPI), for the treatment of refractory metastatic colorectal cancer (mCRC). 20 October 2017
Biolab Pharma is to retrofit a facility in Ontario, Canada, creating a new 13,000 square foot R&D center to develop cardiology and dermatology drugs for the European market. 20 October 2017
Shanghai Pharmaceuticals is attempting to buy the China division of US giant Cardinal Health, in a deal which could be worth up to $1.5 billion, according to estimates of the company's worth. 19 October 2017
Switzerland-based Roivant Sciences it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication, in what is the first collaboration between the two companies. 19 October 2017
The Medicines Discovery Catapult, the UK government-backed body that seeks to speed drug discovery and development, has launched a project with Antruk Enterprises to find new approaches to tackling anti-microbial resistance (AMR). 19 October 2017
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024